RxDoctor Payments Data

David Perrone, MD

Family Medicine · Easton, PANPI 1770529562

Payments from drug & device makers

$2,327in general payments, 2019–2025

Across 43 payments — averaging $54.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$490
  • Novo Nordisk$142
  • AbbVie$131
  • Gilead$116
  • Exact Sciences$67
  • plus $203 from 8 others

What the payments were for

  • Food & beverage$2,327100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,327 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$79,210
Medicare patients
258
Services billed
1,173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban64$55,366
JanuviaSitagliptin Phosphate34$38,025
JardianceEmpagliflozin26$34,638
EntrestoSacubitril/Valsartan18$18,729
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl182$17,864
TradjentaLinagliptin18$14,572
Breo ElliptaFluticasone/Vilanterol24$11,024
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$10,761
OzempicSemaglutide11$10,265
SuboxoneBuprenorphine Hcl/Naloxone Hcl14$9,543
Buprenorphine Hcl90$4,196
Albuterol Sulfate HfaAlbuterol Sulfate63$2,475
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$2,273
Atorvastatin Calcium173$2,178
Pantoprazole Sodium81$1,699

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$41$55,36664 claims
Boehringer IngelheimJardiance, Tradjenta$12$49,21044 claims
GSKBreo Ellipta, Trelegy Ellipta$490$21,78641 claims
NovartisEntresto$11$18,72918 claims
Novo NordiskOzempic$142$10,26511 claims
Indivior Inc.Suboxone$47$9,54314 claims
AbbVieSynthroid$131$73916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Easton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →